Trade Report: Today, BioLineRx Ltd. (BLRX) Receives Buy Rating from Roth Capital

Today, BioLineRx Ltd. (BLRX) Receives Buy Rating from Roth Capital

BioLineRx Ltd. (NASDAQ:BLRX)‘s stock had its “buy” rating reaffirmed by research analysts at Roth Capital in a note issued to investors on Monday. They currently have a $7.00 target price on the stock.

Several other brokerages have also issued reports on BLRX. Maxim Group set a $1.00 target price on BioLineRx and gave the stock a “hold” rating in a research note on Tuesday, November 22nd. Zacks Investment Research lowered BioLineRx from a “buy” rating to a “hold” rating in a research note on Tuesday, October 11th. Finally, S&P Equity Research cut their target price on BioLineRx from $1.24 to $1.10 in a research note on Friday, September 23rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $2.68.

Shares of BioLineRx (NASDAQ:BLRX) traded down 2.8796% during mid-day trading on Monday, hitting $1.0489. 123,172 shares of the stock traded hands. BioLineRx has a 52 week low of $0.71 and a 52 week high of $1.63. The firm’s 50-day moving average is $0.00 and its 200-day moving average is $0.00.

BioLineRx (NASDAQ:BLRX) last issued its earnings results on Tuesday, November 22nd. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by $0.01. Equities analysts forecast that BioLineRx will post ($0.28) earnings per share for the current fiscal year.

A number of hedge funds have recently made changes to their positions in BLRX. KCG Holdings Inc. increased its stake in shares of BioLineRx by 414.1% in the third quarter. KCG Holdings Inc. now owns 151,029 shares of the company’s stock valued at $174,000 after buying an additional 121,650 shares during the last quarter. Morgan Stanley increased its position in shares of BioLineRx by 13.8% in the third quarter. Morgan Stanley now owns 551,122 shares of the company’s stock worth $634,000 after buying an additional 66,900 shares in the last quarter. Finally, Senvest Management LLC increased its position in shares of BioLineRx by 25.4% in the third quarter. Senvest Management LLC now owns 4,443,500 shares of the company’s stock worth $5,110,000 after buying an additional 900,200 shares in the last quarter. Hedge funds and other institutional investors own 13.53% of the company’s stock.

About BioLineRx

Related posts

Leave a Comment